Oscar Health Stock Is Up 100% and Wall Street Is Finally Starting to Take Notice

Oscar Health (OSCR) leverages a tech-driven platform and innovative insurance offerings to differentiate in the ACA marketplace.

OSCR exhibits strong technical momentum and maintains a 100% "Buy" opinion from Barchart.

OSCR is gaining investor attention, trading near all-time highs, and is expected to achieve profitability soon amid high volatility.

Valued at $9.21 billion, Oscar Health (OSCR) operates as a healthcare technology company in the United States and provides health insurance plans to individuals, families, and employees, primarily through the Affordable Care Act (ACA) marketplaces.

I found today's Chart of the Day by using Barchart's powerful screening functions to sort for stocks with the highest technical buy signals; superior current momentum in both strength and direction, Weighted Alpha above 50+ and a 60-Month Beta over 1.5. I then used Barchart's Flipcharts feature to review the charts for consistent price appreciation. OSCR checks those boxes. The Trend Seeker issued a new "Buy" signal on June 4. Since then, the stock has gained 31.14%.

Oracle Stock Crashes to a 52-Week Low. Here's Why It Might Be Time to Buy.

Costco vs. Walmart: 1 Dividend-Paying Retail Giant Stands Above the Other

Editor's Note: The technical indicators below are updated live during the session every 20 minutes and can therefore change each day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the Barchart.com website when you read this report. These technical indicators form the Barchart Opinion on a particular stock.

The stock recently traded at $30.95 with a 50-day moving average of $25.84.

OSCR has made 7 new highs and gained 10.05% over the past month.

Revenue is projected to grow 58.31% this year and another 6.70% next year.

Earnings are estimated to increase 162.92% this year and an additional 40.10% next year.

The Wall Street analysts followed by Barchart give the stock 3 "Strong Buy," 1 "Moderate Buy," 7 "Hold" and 1 "Moderate Sell" opinions with price targets between $13 and $35.

Morningstar thinks the stock is 11% overvalued with a fair value of $27.50.

16,730 investors are following the stock on Seeking Alpha, which rates it a "Strong Buy."

Short interest is 6.22 of the float with 2.74 days to cover the float.

The stock is beginning to be noticed, and Oscar Health seems on track to be profitable soon.